Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 12, 2016. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It strictly reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| October 11, 2016 | Ordinary Shares (25p each) | £17.2781 | 14 to 16 shares per individual | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine equity compensation transactions for eleven senior executives, including the CEO, CFO, and CEO Designate. All transactions were acquisitions of partnership and matching shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Transaction Nature: All reported trades were acquisitions of ordinary shares under the ShareReward Plan, not open market sales.
- Participants: Transactions involved 11 senior executives, including Sir Andrew Witty (CEO), Mr. S. Dingemans (CFO), and Ms. E. Walmsley (CEO Designate).
- Volume: Individual transaction volumes were minimal, ranging from 14 to 16 shares per executive.
- Pricing: All shares were acquired at a uniform price of £17.2781.
- Financial Data: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for financial metrics.